Insulet appoints Flavia Pease as new chief financial officer

Insulet Corporation (NASDAQ: PODD) announced that Flavia Pease will succeed Ana Maria Chadwick as executive vice president and chief financial officer, effective September 30, 2025. Chadwick will transition to a senior advisor role to facilitate the change.

Pease brings extensive healthcare and medical technology experience to the insulin pump manufacturer. She most recently served as corporate executive vice president and chief financial officer at Charles River Laboratories. Prior to that role, she spent more than 20 years at Johnson & Johnson, including positions as vice president and group chief financial officer of the company's global Medical Devices business, overseeing financial operations for a $27 billion portfolio.

Pease has served on Insulet's board of directors and audit committee since January 2024. She will resign from the board upon assuming her new role. Her background includes leadership positions across Johnson & Johnson's Medical Devices and Pharmaceutical segments, as well as experience at SC Johnson and in investment banking.

"Flavia is a highly accomplished business leader with world-class healthcare and MedTech expertise," said Ashley McEvoy, Insulet's president and chief executive officer. The company stated that Pease's experience in global organizations and financial performance management align with Insulet's growth objectives.

Pease holds a Bachelor of Science in Economics from Pontifícia Universidade Católica in Rio de Janeiro, Brazil, and a Master of Business Administration from Santa Clara University.

Insulet also announced it expects to exceed its previously issued third quarter 2025 total revenue growth guidance, driven by strong new customer starts in both U.S. and international markets. The company plans to provide additional details during its third quarter earnings call scheduled for November 6, 2025.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ:
• Corvus Pharmaceuticals publishes soquelitinib Phase 1 T cell data in Blood
• New America Acquisition names new CFO and COO after leadership shift